Remedium Lifecare Limited has officially completed its transformation to Supha Pharmachem Limited following approval from the Ministry of Corporate Affairs. The pharmaceutical company, which specializes in Active Pharmaceutical Ingredients (APIs) and intermediates, received the Certificate of Incorporation pursuant to change of name on December 15, 2025.

Official Name Change Approval

The Office of the Central Processing Centre, Ministry of Corporate Affairs, issued the Certificate of Incorporation pursuant to change of name on December 15, 2025. The company has been officially renamed from Remedium Lifecare Limited to Supha Pharmachem Limited with effect from December 15, 2025.

Shareholder Approval Background

Prior to the official approval, shareholders had overwhelmingly supported the name change through a postal ballot, with over 97.00% approval. The special resolution was part of three key resolutions that also included important board appointments.

New Board Leadership

Alongside the name change, the company confirmed two significant board appointments:

Executive Leadership

Mr. Vignesh Laxman Gawde was appointed as Executive Director for a five-year term. Mr. Gawde holds an M.Sc. in Physical Chemistry from the Institute of Science, Mumbai University.

Board Chairman

Mr. Rambhajan Vishwakarma was appointed as Non-Executive Director and Chairman of the Board, bringing over 15 years of experience in banking product sales.

Implementation and Next Steps

The company has informed BSE Limited about the official name change and will process the necessary applications with the stock exchange. All company records and documents will be updated to reflect the new name - Supha Pharmachem Limited. As per regulatory requirements, the company must display both the old and new names at all required locations for a period of two years.

Corporate Details

The successful completion of the name change to Supha Pharmachem Limited represents a significant milestone in the company's evolution, potentially signaling a new strategic direction in the pharmaceutical industry.

Remedium Lifecare Limited has announced significant changes to its board composition and committee structure, as per a recent filing with the BSE. The company's Board of Directors, in a meeting held on October 31, 2025, approved several key appointments and restructuring measures.

New Board Appointments

The company has made two notable appointments to its board:

1. Mr. Rambhajan Vishwakarma (DIN: 11360922) has been appointed as an Additional Director (Non-Executive, Non-Independent) and Chairman of the Board, effective October 31, 2025.
2. Mr. Vignesh Laxman Gawde (DIN: 11360925) has been appointed as an Additional Executive/Whole-time Director for a five-year term, also effective from October 31, 2025.

Both appointments are subject to shareholder approval within three months or at the next General Meeting, whichever is earlier.

Director Profiles

Board Committee Restructuring

The company has reconstituted four key committees:

1. Audit Committee: Now chaired by Mr. Vijay Pal Singh Gulya (Independent Director)
2. Nomination and Remuneration Committee: Chaired by Mrs. Shamim Adil Michal (Independent Director)
3. Stakeholders Relationship Committee: Chaired by Mr. Rambhajan Vishwakarma
4. Risk Management Committee: Chaired by Mrs. Shamim Adil Michal

It's worth noting that the Nomination and Remuneration Committee was dissolved prior to these appointments due to director resignations, which prevented their recommendation for the new appointments.

Postal Ballot and Other Approvals

The board has approved postal ballot notices for:

1. Change of the company name
2. Regularization of Mr. Rambhajan Vishwakarma's appointment
3. Regularization and remuneration approval for Mr. Vignesh Laxman Gawde

The e-voting for these resolutions is scheduled to conclude on December 7, 2025.

These changes mark a significant restructuring of Remedium Lifecare's leadership and governance structure, potentially signaling a new direction for the company's operations and strategy.